ReviewMedicine2026
A case report and literature review of neuropsychiatric lupus presenting with coma as the initial symptom.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleNeuropsychiatric lupus (NPSLE) represents a severe disease manifestation where early recognition significantly impacts prognosis. This report highlights the diagnostic challenges and management strategies in NPSLE presenting with coma, aiming to enhance clinical awareness of this life-threatening condition. PATIENT CONCERNS: A 20-year-old female presented with acute coma of unknown origin. Initial evaluation revealed nonspecific cerebral edema on neuroimaging, while symptomatic treatment yielded minimal improvement. Physical examination showed gangrene of the right toes, indicating significant vascular compromise. DIAGNOSES: According to the 2019 EULAR management recommendations for systemic lupus erythematosus (SLE), this patient first meets the diagnostic criteria for SLE: positive antiphospholipid antibodies (antinuclear antibody), positive anti-double-stranded DNA antibodies, positive anti-Smith antibodies, decreased complement component 3 and complement component 4 levels, with a total classification criteria score ≥ 10 points, confirming the diagnosis of SLE. Subsequently, the patient developed neuropsychiatric symptoms as defined by the guidelines. After comprehensive exclusion of non-SLE related causes including infections, encephalitis, and metabolic abnormalities, combined with specific laboratory findings (the aforementioned autoantibodies and complement abnormalities) and imaging results, a final diagnosis of NPSLE was established.
interventionsTreatment comprised methylprednisolone pulse therapy (500 mg daily for 3 days) followed by maintenance corticosteroids, combined with intravenous immunoglobulin (25 mg daily for 5 days) and cyclophosphamide (400 mg weekly). Adjunctive measures included mannitol for cerebral edema management and appropriate analgesic therapy. OUTCOMES: The patient regained consciousness by day 5, followed commands despite residual right-sided weakness (grade 2). Significant motor improvement (grade 4 strength) occurred by day 12, supported by neuroimaging showing reduced cerebral lesions. Discharge occurred on day 18 with substantial neurological recovery, though digital necrosis persisted. LESSONS: Unexplained coma in young females warrants consideration of autoimmune etiologies. Comprehensive immunological testing is crucial for accurate diagnosis. The combination of methylprednisolone, immunoglobulin, and cyclophosphamide demonstrated significant efficacy in severe NPSLE. Early recognition and aggressive immunosuppressive therapy are vital for optimizing outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.